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Abstract Using PCR-based techniques, we have isolated and 
sequenced the full-length cDNAs that encode the human neuronal 
nAChR subunits a3,4,5,7 and 1l2,3,4 in the neuroblastoma cell 
lines SH-SY5Y and/or IMR-32. The predicted nAChR 1l3- and 
Jl4-subunit proteins contain 458 and 498 amino acids, respec-
tively. Except for the 1l2, all the other cloned cDNAs showed 
differences with the published sequences. Northern blots show 
expression of the nAChR subunits a3,7 and 1l2,4 in the human 
neuroblastoma cell line SH-SY5Y, with intensity of the 
hybridisation signal decreasing in the order a3 > Jl4 > 112 > a7. 
Key words: Neuroblastoma; Nicotinic receptor; 
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1. Introduction 
Nicotinic acetylcholine receptors (nAChRs) are members of 
a superfamily of ligand-gated ion channels that mediate fast 
signal transmission at synapses ([1] review). The nAChRs are 
presumed to be (hetero )pentamers of homologous subunits. 
The subunits that constitute muscle and neuronal forms of 
vertebrate nAChRs are the product of separate genes and 
differ in primary structure [2]. The neuronal nAChRs are di-
vided into several subtypes that are formed through varying 
combinations of homologous subunits arranged around a cen-
tral channel [3]. A variety of nAChR subunits have been 
identified in the nervous system in recent years ([4,5] reviews). 
They are classified as a-subunits (a2-a9) if they share, as part 
of the presumed acetylcholine binding site, a pair of adjacent 
cysteines with the aI-subunit of the muscle-type nAChR. Sub-
units lacking these cysteine residues are called ~-subunits (~2-
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Abbreviations: nAChR, nicotinic acetylcholine receptor; TD-PCR, 
touch-down polymerase chain reaction; RACE, rapid amplification of 
cDNA ends; Tm, melting temperature; nt, nucleotide; bp, base pair; 
kb, kilobase; dNTP, deoxynucleotide triphosphate; UTR, untrans-
lated region; GSP, gene-specific primer; AP, adapter primer; MEM, 
modified Eagle's medium; DMEM, Dulbecco MEM; DMSO, 
dimethylsulphoxide; SDS, sodium dodecyl sulphate; SSC, standard 
sodium chloride/sodium citrate buffer; SSPE, standard sodium 
chloride/sodium phosphate/ethylene diamine tetraacetate buffer 
The nucleotide sequence data for nAChR subunits a3,4,5,7 and ~2,3,4 
were deposited in the EMBL, GenBank and DDBJ Nucleotide 
Sequence Databases under the accession numbers Y08415 to Y08421. 
~4). To date, cDNAs encoding seven gene products (a3,4,5,7 
and ~2,3,4) have been isolated from different human tissues. 
For two subunits, ~3 and ~4, the 5' coding region remains 
unknown. In this report we describe the cloning, using PCR-
based techniques, and sequence of the full-length coding re-
gion of the nAChR subunits a3,4,5,7 and ~2,3,4 from the 
human neuroblastoma cell lines SH-SY5Y and/or IMR-32. 
Furthermore, we show the expression, with Northern blots, 
of the nAChR subunits a3,7 and ~2,4 in the SH-SY5Y cell 
line. 
2. Material and methods 
2.1. Materials 
Dimethylsulphoxide (DMSO) was from Sigma, St. Louis, MO, 
USA. Guanidinium thiocyanate and glyoxal were from Fluka Chemie, 
Bomem, Belgium. Takara ExTaq polymerase was from Imtec Diag-
nostics, Antwerp, Belgium. Pfu polymerase was from Stratagene, Hei-
delberg, Germany. MgCh, dNTPs, and 10xPCR buffer II were from 
Perkin Elmer Cetus, Zaventem, Belgium. The [a32P]dCTP was from 
NEN, Brussels, Belgium. Caesium chloride, restriction endonucleases 
and herring sperm DNA were from Boehringer, Mannheim, Ger-
many. Low melting point agarose was from FMC Bioproducts, Rock-
land, ME, USA. The RNA molecular size standard and all media for 
cell culture were from Gibco BRL, Merelbeke, Belgium. The pUC18 
vector was from Pharmacia, Roosendaal, The Netherlands. Multi-
prime DNA labeling system was from Amersham, Gent, Belgium. 
Marathon cDNA amplification kit, 1st-strand cDNA synthesis kit 
and Taq-start antibody were from Clontech, Leusden, The Nether-
lands. PolyATtract mRNA Isolation System I, and Wizard Clean-Up 
system were from Promega, Leiden, The Netherlands. Zeta Probe 
nylon membrane, ion exchange mixed bed resin (AG 501-X8) and 
SDS were from Biorad, Brussels, Belgium. Formamide was from Jans-
sen, Beerse, Belgium. Human pons and human frontal cortex tissue 
were a generous gift of Dr. P. Cras, University of Antwerp, Belgium. 
All other chemicals were of analytical grade and were obtained from 
Merck, Darmstadt, Germany. Primers for PCR and DNA sequencing 
were designed with the Genetics Computer Group (GCG) sequence 
analysis package version 8 (GCG, Madison, WI, USA). All primers 
have three additional non-complementary nucleotides at the 5' end in 
case the Pfu DNA polymerase does not copy a DNA strand all the 
way to the end. All oligonucleotides (Table 1) were synthesised by 
MWG-Biotech (Ebersberg, Germany), HPLC-purified and checked 
for homogeneity by capillary electrophoresis. 
2.2. Mammalian cell culture 
Cells were cultured in a 95% air/5% CO2 humidified incubator at 
37°C. The human neuroblastoma cell line IMR-32 was obtained from 
the American Type Culture Collection (ATCC, eCL-I27, batch F-
11534). Cells were cultured in modified Eagle's medium (MEM) sup-
plemented with 10% (v:v) heat-inactivated fetal calf serum, 100 U/ml 
penicillin G, 100 Ilg/ml streptomycin sulphate, 1 mM pyruvate and 2 
mM L-glutamine. 
The human neuroblastoma cell line SH-SY5Y (thrice cloned sub-
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line of SK-N-SH) was initially provided by June Biedler and Barbara 
Spengler of the Sloan Kettering Institute for Cancer Research (6). 
Cultures were grown in a I: I mixture of Ham's FI2 medium and 
Dulbecco modified Eagle's medium (DMEM) supplemented with 
15% (v:v) heat-inactivated fetal calf serum, 100 U/ml penicillin G, 
100 flg/ml streptomycin sulphate, I mM pyruvate and 2 mM L-glu-
tamine. 
2.3. Preparation of polyA+ mRNA 
Total RNA was extracted by dissolving the cells in guanidinium 
thiocyanate buffer followed by centrifugation on a discontinuous cae-
sium chloride gradient as described (7). Poly A + mRNA was isolated 
with the PolyATtract mRNA Isolation System I according to the 
manufacturer's instructions. 
2.4. 5' RACE PCR amplification of cDNAs encoding nAChR /33- and 
f34-subunits 
Three gene-specific primers, GSPI, 2 and 3 (Table I, Fig. I), were 
designed for each subunit based on the published sequences [8,9). 
Adapter-ligated oligo(dT)-primed cDNA and adapter-ligated inter-
nally primed cDNA batches were prepared from the IMR-32 cell 
line and human pons tissue with the Marathon cDNA amplification 
kit according to the manufacturer's instructions. To obtain oligo(dT)-
primed cDNAs the oligo(dT) cDNA synthesis primer (Marathon 
kit) was used. For preparation of the internally primed cDNAs, the 
GSPI (~3-GSPI and ~4-GSPI) primers were used. The cDNA batches 
were prepared in a final volume of 250 fll. Of each cDNA batch, 5 fll 
was used in a 50 fll first-round TD-PCR with the adapter primer I 
(API, Marathon kit) and the GSP2 for 40 cycles each consisting of (a) 
I min at 94°C, (b) I min at noc, gradually (0.3°C/cycle) decreasing to 
65°C, and (c) 3 min at n°c. In the reaction mixture 2.5 units of 
Takara Ex-Taq polymerase with corresponding buffer, 0.55 flg Taq-
start antibody, 0.2 flM of each primer, 5% (v:v) DMSO and 0.2 mM 
dNTPs were used. A second-round nested PCR was performed with 
0.5 fll of the first-round PCR sample, the AP2 (Marathon kit) and the 
GSP3. The composition of the PCR reaction was the same as in the 
first-round PCR. 
2.5. PCR amplification of full-length cDNAs encoding nAChR 
aJ,4,5,7- and j32,3,4-subunits 
Gene-specific primers (Table I) were designed for the a3,4,5,7- and 
~2-subunit based on published sequences [10-14). For the ~3- and ~4-
subunits, gene-specific anti-sense (based on the published sequence 
[8,9]) and sense (based on the 5' RACE sequence) primers were de-
signed. Both oligo(dT)- and random-primed cDNA batches were pre-
pared from polyA + mRNA of the IMR-32 and SH-SY5Y cell lines, 
and of human frontal cortex tissue, with the 1st-strand cDNA syn-
thesis kit according to the manufacturer's instructions in a final vol-
ume of 100 fll. Of each cDNA batch 5 fll was used in a 50 fll PCR. 
First-round TD-PCR was performed with the 5A13A primer combi-
nation (Table I) for 30 cycles consisting of (a) I min at 94°C, (b) I min 
at 5°C above the calculated Tm value, gradually (0.5°C/cycle) decreas-
ing to 10°C below the calculated Tm value and (c) 3 min at 75°C. This 
was followed by 0, 5, 10 or 15 additional cycles of (a) I min at 94°C, 
(b) I min at 10°C below the calculated Tm value and (c) 3 min at 
75°C. The reaction mixture contained 1.25 units of Pfu polymerase, 
0.5 flM of each primer, 5% (v:v) DMSO, I xPCR buffer 11,0.2 mM 
dNTPs, and MgCh at concentrations ranging from 0.5 to 3.0 mM. 
PCR samples were separated on a I % low melting point agarose gel, 
bands of the correct size were cut out, purified with the Wizard Clean-
Up system and dissolved in 50 fll MilliQ-water (Millipore). With 0.5 
fll of the purified first-round PCR fragment and the 5/3 primer com-
bination a second-round nested PCR was performed for 15, 20 or 25 
cycles «a) I min at 94°C, (b) I min at 5°C below the calculated Tm 
value, and (c) 3 min at 75°C). The composition of the PCR reaction 
was the same as in the TD-PCR. 
2.6. Cloning PCR products in pUC18 and DNA sequencing 
The PCR fragments were size-fractionated on a 1% low melting 
point agarose gel, bands of the correct size were cut out, purified 
with the Wizard Clean-Up system, and ligated into the dephosphoryl-
ated Smal site of the pUCI8 vector. Sequencing was done by Dye 
Terminator cycle sequencing (Perkin Elmer, ABI Division, Foster, 
CA, USA) with custom primers. All sequencing gels were run on an 
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Applied Biosystems 373A or 377 sequencing apparatus. Each insert 
was sequenced fully on both strands. 
2.7. Northern blot analysis 
De-ionised glyoxallDMSO, Denhardt's solution, SSPE, and SSC 
were prepared as described (7). Approximately 3 flg of poly A + 
RNA from the SH-SY5Y cell line was denatured with de-ionised 
glyoxallDMSO, and size-fractionated on a 1% agarose gel as de-
scribed (7). The marker lane containing the 0.24-9.5 kb RNA ladder 
was cut off, stained with ethidium bromide (0.5 flg/ml) for 30 min and 
- aligned with a fluorescent ruler - photographed under ultraviolet 
trans-illumination. The 10glO of the size of the RNA standards was 
plotted against the distance migrated. The resulting regression line 
was used to calculate the size of the RNA transcripts on auto radio-
graphs. The RNA gel containing the polyA + samples was vacuum-
blotted with 0.1 N NaOH onto a Zeta probe nylon membrane. Full-
length cDNA probes were labelled with [a-32P)dCTP using the Multi-
prime DNA labelling system according to the manufacturer's instruc-
tions. Hybridisation was performed overnight at 42°C in a solution 
containing 50% (v:v) formamide, 5 X SSPE, 5 x Denhardt's solution, 
0.1% (w:v) SDS and 100 flg/ml denatured herring sperm DNA. Blots 
were finally washed at 60°C in 0.1 X SSC containing 0.1 % SDS for 16 
h and exposed to Kodak X-omat AR film at -70°C in cassettes 
containing two Dupont Cronex lightning plus-T intensifying screens. 
a) AP-2 
AP-J 
5'-CCAICCTAAIACGACTCACIATAGGGCTCGAGCGGCCGCCCGGGCA 
1 ~*TGTTGCTGTCCTCTTGGGTTCCACTTCGGATTTTGAACCCCT 
43 GTATTTTCTTTTCAAAACCCCCTTTTCCAATGGAAATGCTCTGTTG 
89 TTAAAAAGGAAGAAACTGTCTTTCTGAAACTGACATCACG~CTC 
135 CCAGATTTTATGCTGGTTCTCATCGTCCTTGGCATCCCTTCCTCAG 
181 CCACCACAGGTTTCAACTCAATCGCCGAAAATGAAGATGCCCTCCT 
227 CAGACATTTGTTCCAAGGTTATCAGAAATGGGTCCGCCCTGTATTA 
273 CATTCTAATGACACCATAAAAGTATATTTTGGATTGAAAATATCCC 
319 AGCTTGTAGATGTGGATGAAAAGAATCAGCTGATGACAACCAATGT 
365 GTGGCTCAAACAGGAATGGACAGACCACAAGTTACGCTGGAATCCT 
411 GATGATTATGGTGGGATCCATTCCATTAAAGTTCCATCAGAATCTC 
457 TGTGGCTTCCTGACATAGTTCTCTTTGAAAATGCTGACGGCCGCTT 
4 (33-GSP3 
503 CGAAGGCTCCCTGATGACCAAGGTCATCGTGAAATCAAACGGAACT 
549 GTTGTCTGGACCCCTCCCGCCAGCTACAAAAGCTCCTGCACCATGG 
(33-GSP2 
595 ACGTCACGTTTTTCCCGTTCGACCGACAGAACTGCTCCATGAAGTT 
.. (33-GSPI 
641 TGGATCCTGGACTTATGATGGCAC .......... -3' 
b) AP-2 
AP-J 
5'-CCATCCTAATACGACTCACIATAGGGCTCGAGCGGCCGCCCGGGCA 
1 ~*CTGGACCGGCGCTCACTCGACCGCGCGGCTCACGGGTGCCCT 
43 GTGACCCCACAGCGGAGCTCGCGGCGGTTGCCACCCGGCCCCGCCG 
89 GCC~AGGCGCGCGCCTTCCCTGGTCCTTTTCTTCCTGGTCGCCC 
135 TTTGCGGGCGCGGGAACTGCCGCGTGGCCAATGCGGAGGAAAAGCT 
181 GATGGACGACCTTCTGAACAAAACCCGTTACAATAACCTGATCCGC 
227 CCAGCCACCAGCTCCTCACAGCTCATCTCCATCAAGCTGCAGCTCT 
273 CCCTGGCCCAGCTTATCAGCGTGAATGAGCGAGAGCAGATCATGAC 
319 CACCAATGTCTGGCTGAAACAGGAATGGACTGATTACCGCCTGACC 
365 TGGAACAGCTCCCGCTACGAGGGTGTGAACATCCTGAGGATCCCTG 
.. (34-GSP3 
411 CAAAGCGCATCTGGTTGCCTGACATCGTGCTTTACAACAACGCCGA 
- (34-GSP2 4 (34-GSPI 
457 CGGGACCTATGAGGTGTCTGTCTACACCAACT ........... -3' 
Fig. 1. The 5' end sequences obtained with the 5' RACE PCR of 
the human nAChR subunits ~3 (a) and ~4 (b). The position of the 
gene-specific primers (GSP) and the adapter primers (AP) are indi-
cated. The nucleotide sequence of the adapter and the putative start 
codon are underlined. 
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Table I 
Primers used for the amplification of the 5' end (GSPs) and the 
full-length coding region of the a3,4,5,7- and ~2,3,4-subunits 
Primer 
~3-GSPI 
~3-GSP2 
~3-GSP3 
~4-GSPI 
~4-GSP2 
~4-GSP3 
a3-5A 
a3-5 
a3-3A 
a3-3 
a4-5A 
a4-5 
a4-3A 
a4-3 
a5-5A 
a5-5 
a5-3A 
a5-3 
a7-5 
a7-3 
~2-5A 
~2-5 
~2-3A 
~2-3 
~3-5A 
~3-5 
~3-3A 
~3-3 
~4-5A 
~4-5 
~4-3 
3. Results 
5' - sequence -3' 
GAAGTGCCATCATAAGTCCAG 
GTTAACGTGACGTCCATGGTGCAGG 
GAATCACGATGACCTTGGTCATCAGGG 
GTTAGTTGGTGTAGACAGACACC 
GAAGTCGGCGTTGTTGTAAAGCACGATG 
CATAAGCACGATGTCAGGCAACCAGATG 
CAACCACCAGCCATGGCTCTG 
GTAGCCACCATGGCTCTGGCCGTCTCG 
GAACAGGCAGGCACACAGCTTAG 
GTGTTATGCATCTTCCCTGGCCATCAGG 
GAACACAGGAGAAGACGAACCGGG 
CGAGCCACCATGGAGCTAGGGGGCCC 
GTTGCTCCCGGTCCCTTCCTAGATC 
CCACTAGATCATGCCAGCCAGCCAGG 
GAAGCTCCATTCCCCAAGAGTTCG 
CAAGCCACCATGGCGGCGCGGGG 
GTTATGTATACTTCAGTCCCTTGGGAGGC 
CGTGCTTCACTTATTTGCATTTCCAATATGAACTGG 
CAAGGATCCGCCACCATGCGCTGCTCGCC 
GAATTACGCAAAGTCTTTGGACACG 
GATTAGGCGAGGCAGCGAGCTATG 
GAAGCCACCATGGCCCGGCGCTG 
GTTAGGGTGGCTGGGTGAAAGAGC 
CTAGGATCCTCACTTGGAGCTGGGGGC 
GGTGAATTCTGTTGCTGTCCTCTTGGGTTCC 
GGTGAATTCGCCACCATGCTCCCAGATTTTATGCTG 
GCATCTAGACGTAGAACAAGCACATGCATTTGG 
GGTTCTAGACTAATGGTAACTATGTAGCCACATCTTC 
GATCGACTCACTATAGGGCTCGAGCGG 
GAAGCCACCATGAGGCGCGCGCC 
GTTTCAGTCACGCTGGGCAGCGTAG 
3.1. Cloning and sequence of the 5' end of the human nAChR 
/33- and f34-subunit cDNAs 
To obtain the 5' end of the human nAChR ~3- and ~4-
subunits we chose the 5' RACE method [15]. Adapter-ligated 
oligo(dT)-primed cDNA and adapter-ligated internally 
primed cDNA were prepared from 1 I1g of IMR-32 polyA + 
mRNA. After a first round of 5' RACE PCR a ,..., 500 bp 
reaction product was obtained with the ~4-GSP2/API primer 
combination (Fig. 1), starting from either internally primed or 
oligo(dT)-primed cDNA preparations. After a second nested 
round of PCR, with the ~4-GSP3/AP2 primer combination 
(Fig. 1), the expected ,...,470 bp PCR product could be de-
tected for both cDNA preparations. No specific PCR product 
could be detected for the ~3-subunit. To obtain the 5' end of 
the ~3-subunit mRNA we decided to use human pons because 
it has been shown that the ~3-subunit is expressed in this 
brain region [8]. From 1 I1g of human pons polyA + mRNA, 
adapter-ligated oligo(dT)- and adapter-ligated internally 
primed cDNA were prepared. After a first round of 5' 
RACE PCR with the ~3-GSP2/API primer combination 
(Fig. 1), no specific PCR products for either cDNA prepara-
tions could be detected. However, a second nested round of 
PCR with the ~3-GSP3/AP2 primer combination (Fig. 1) 
yielded a PCR product of ,..., 570 bp starting from the inter-
nally primed cDNA preparation. The two ,..., 500 bp ~4 and 
the 570 bp ~3 PCR products were cloned into the dephos-
phorylated SmaI site of the pUCI8 vector and the nucleotide 
sequence was determined (Fig. 1). Compared to the published 
incomplete sequences [8,9], 240 nt of additional 5' end ~3 
sequence and 231 nt (internally primed cDNA preparation) 
or 226 nt (oligo(dT)-primed cDNA preparation) of additional 
5' end ~4 sequence were obtained. Combining these sequence 
data with the published sequences, an open reading frame of 
1374 nt for the ~3-subunit and of 1494 nt for the ~4-subunit 
could be identified. 
3.2. Cloning and sequence of the full-length human nAChR 
aJ,4,5,7- and /32,3,4-subunits 
To obtain full-length clones of 0.3,4,5,7- and ~2,3,4-subunits 
we designed primers to amplify by TD-PCR their coding re-
gion exactly from the start to the stop codon (included) and 
adding the Kozak consensus sequence (GCCACC) upstream 
of the start codon. With this strategy we were able to amplify 
the human nAChR o.7-subunit from the neuroblastoma cell 
lines SH-SY5Y and IMR-32 (Table 2). None of the other 
subunits could be amplified using the same strategy, notwith-
standing numerous attempts to optimise PCR conditions (dif-
ferent concentrations of MgCIz, DMSO, glycerol, formamide, 
cDNA and primers, different annealing temperatures and 
number of PCR cycles). 
Therefore, a different strategy to amplify the other subunits 
was chosen: nested PCR. This permits the choice of optimum 
PCR primers in the first round, combined with amplification 
in the second round of the exact coding region with primers 
that may be less than ideal due to the strict constraints on 
their 5' ends. In the first round of TD-PCR, primers directed 
to the sequence upstream of the start codon (SA sense, Table 
1) and downstream of the stop codon (3A anti-sense, Table 1) 
were used. The primers were designed as ideal as possible 
(length: 20 nt, GC content: 50%, same T m value (,..., 70°C) 
for both sense and anti-sense primers). Six MgCIz concentra-
tions ranging from 0.5 to 3.0 mM (in 0.5 mM increments) 
were used and the number of PCR rounds kept to a mini-
mum. The DNA fragment of the expected size was isolated 
and used in a second nested PCR with the primers amplifying 
Table 2 
PCR amplification conditions for the coding region of the human 
nAChR a3,4,5,7- and ~2,3,4-subunits 
Subunit Source [MgCbJ First TD-PCR Nested PCR 
a3 SH-SY5Y 1.0 mM 1550 bp, 0 1521 bp, 15 
IMR-32 1.0 mM 1550 bp, \0 1521 bp, 20 
a4 SH-SY5Y all X X 
IMR-32 1.0 mM 2043 bp, 15 1896 bp, 15 
a5 SH-SY5Y 1.5 mM 1519 bp, 0 1419 bp, 15 
IMR-32 1.5 mM 1519 bp, 0 1419 bp, 20 
a7 SH-SY5Y 2.0mM 1527 bp, 15 
IMR-32 2.0mM 1527 bp, 15 
~2 SH-SY5Y 1.5 mM 1584 bp, 0 1527 bp, 15 
IMR-32 1.5 mM 1584 bp, 0 1527 bp, 25 
H.F.C. 1.5 mM 1584 bp, 15 1527 bp, 20 
~3 SH-SY5Y 2.5 mM 1613 bp, 15 1400 bp, 25 
IMR-32 all X X 
Human pons 2.5 mM 1613 bp, 15 1400 bp, 25 
~4 SH-SY5Y 1.0 mM 1566 bp, 0 1507 bp, 20 
IMR-32 1.0 mM 1566 bp, 0 1507 bp, 20 
For each RNA source, the optimal [MgCbJ is listed as well as the 
predicted DNA fragment length followed by the number of additional 
PCR cycles after the initial 30 cycles in the first TD-PCR or the total 
number of cycles in a second (nested PCR) round (bp, x). 
X = no specific PCR product obtained; all = all [MgCbJ tested gave 
similar results; H.F.C. = human frontal cortex tissue. 
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• Signal Peptide , 
~2 ••.•• MARRCGPVALLLGFGLLR •••••••••...• LCSGVWGTDTEERLVEHLLDPSRYNKLIRPATNGSELVTVQLMVSLAQLISVHEREQIMTT 79 
~4 ••••••• MRRAPSLVLFFLVALC ••.•••••••••• GRGNCRVANAEEKLMDDLLNKTRYNNLIRPATSS SQLI S IKLQLSLAQLISVNER~IMTT 77 
a5 MAARGSGPRALRLLLLVQLVAGRCGLAGAAGGAQRGLSEPSSIAKHEDSLLKDLFQD •• YERWVRPVEHLNDKIKIKFGLAISQLVDVDEKNQLMTT 95 
~3 •.••..••• MLPDFMLVLIV •..•.. LGIPSSATTGF ... NSIAENEDALLRHggG •• YQKWVRPVLHSNDTIKVYFGLKISQLVDVDEKNQLMTT 77 
a3 MALAVSLPLALSPPRLLLLLL ..•••••••• SLLP ...• VARASEAEHRLFERLFED .• YNEIIRPVANVSDPVIIHFEVSMSQLVKVDEVNQIMET 81 
a4 MELGGPGAPRLLPPLLLLLGT •••....••• GLLRASSHVETRAHAEERLLKKLFSG •. YNKWSRPVANISDVVLVRFGLSIAQLIDVDEKNQMMTT 85 
a7 ..................... MRCSPGG~SLLHVSLQGEFQRKLYKELVKN •. YNPLERPVANDSQPLTVYFSLSLLQIMDVDEKNQVLTT 74 
~2 NVWLTQEWEDYRLTWKPEEFDNMKKVRLPSKHIWLPDVVLYNNADGMYEVSFYSNAWSYDGSIFWLPPAIYKSACKIEVKHFP~DQQNCTMKFRSW 176 
~4 NVWLKQEWTDYRLTWNSSRYEGVNILRIPAKRIWLPDIVLYNNADGTYEVSVYTNLIVRSNGSVLWLPPAIYKSACKIEVKYFP~DQQNCTLKFRSW 174 
a5 NVWLKQEWIDVKLRWNPDDYGGIKVIRVPSDSVWTPDIVLFDNADGRFEGT. STKTVIRYNGTVTWTPPANYKSSCTIDVTFFP~DLQNCSMKFGSW 191 
~3 NVWLKQEWTDHKLRWNPDDYGGIHSIKVPSESLWLPDIVLFENADGRFEGSLMTKVIVKSNGTWWTPPASYKSSCTMDVTFFPFDRQNCSMKFGSW 174 
a3 NLWLKQIWNDYKLKWNPSflYGGAEFMRVPAQKIWKPDIVLYNNAVGDFQV'2!2KTKALLKYTGEVTWIPPAIFKSSCKIDVTYFPFDYQNCTMKFGSW 178 
a4 NVWVKQEWHDYKLRWDPADYENVTSIRIPSELIWRPDIVLYNNADGDFAVTHLTKAHLFHDGRVQWTPPAIYKSSCSIDVTFFPFDQQNCTMKFGSW 182 
a7 NIWLQMSWTDHYLQWNVSEYPGVKTVRFPDGQIWKPDILLYNSADERFDATFHTNVLVNSSGHCQYLPPGIFKSSCYIDVRWFPFDVQHCKLKFGSW 171 
+---1MDI 40-
~2 TYDRTEIDLVLKSEVASLDDFTPSGEWDIVALPGRRNENPDDST ••• YVDITYDFIIRRKPLFYTINLIIPCVLITSLAILVFYLPSDCGEKMTLCI 270 
~4 TYDHTEIDMVLMTPTASMDDFTPSGEWDIVALPGRRTVNPQDPS ••• YVDVTYDFIIKRKPLFYT INLIIPCVLTTLLAILVFYLPSDCGEKMTLCI 268 
a5 TYDGSQVDIILEDQDVDKRDFFDNGEWEIVSATGSKGNRTDSCC •• WYPYVTYSFVIKRLPLFYTLFLIIPCIGLSFLTVLVFYLPSNEGEKICLCT 286 
~3 TYDGTMVDLILINENVDRKDFFDNGEWEILNAKGMKGNRRDGVY .. SYPF ITYSFVLRRLPLFYTLFLI IPCLGLSFLTVLVFYLPSDEGEKLSLST 269 
a3 SYDKAKIDLVLIGSSMNLKDYWESGEWAllKAPGYKHDIKYNCCEE!YPDITYSLYIRRLPLFYTINLIIPCLLISFLTVLVFYLpSDCGEKVTLCI 275 
a4 TYDKAKIDLVNMHSRVDQLDFWESGEWVIVDAVGTYNTRKYECCAEIYPDITYAFVIRRLPLFYTINLIIPCLLISCLTVLVFYLPSECGEKITLCI 279 
a7 SYGGWSLDLQM •• QEADISGYIPNGEWDLVGIPGKRSERFYECCKEPYPDVTFTVTMRRRTL YYGLNLLIPCVLI SALALLVFLLPADSGEKISLG I 266 
-1MDII-- +---- TMD 111 __ 
~2 SVLLALTVFLLLISKIVPPTSLDVPLVGKYLMFTMVLVTFSIVTSVCVLNVHHRSPTT. HTMAPWVKWFLEKLPALLFMQQPR. . • • . . • • • • • •• 353 
~4 SVLLALTFFLLLISKIVPPTSLDVPLIGKYLMFTMVLVTFSIVTSVCVLNVHHRSPST. HTMAPWVKRCFLHKLPTFLFMKRPG. . • . . . . • • • . •• 351 
a5 SVLVSLTVFLLVIEEIIPSSSKVIPLIGEYLVFTMIFVTLSIMVTVFAINIHHRSSSTHNAMAPLVRKIFLHTLPKLL£MR. . • • . • • • . . . . • • •• 367 
~3 SVLVSLTVFLLVIEEIIPSSSKVIPLIGEYLLFIMIFVTLSIIVTVFVINVHHRSSSTYHPMAPWVKRLFLQKLPKLLCMK. • • • • • • • • • • . . . •• 350 
a3 SVLLSLTVFLLVITETIPSTSLVIPLIGEYLLFTMIFVTLSIVITVFVLNVHYRTPTT. HTMPSWVKTVFLNLLPRVMFMTRf'. • • • • • • • • • . . •. 357 
a4 SVLLSLTVFLLLITEIIPSTSLVIPLIGEYLLFTMIFVTLS IVITVFVLNVHHRSPRT • HTMPTWVRRVFLDIVPRLLLMKRPSWKDNCRRLIESM 375 
a7 TVLLSLTVFMLLVAEIMPATSDSVPLIAQYFASTMIIVGLSWVTVIVLQYHHHDPDG. GKMPKWTRVILLNWCAWFLRMKRPG. • • • • • • • • . . .• 349 
Cytoplasmic Region 
~2 ••••••••••••••••• HHCARQR. LRLRRRQREREGAGALFFREAPGADSCTCFVNRASVQGL. • . • . . . . • • • • • • • • • • • • • . . . . . • • • • • •• 399 
~4 •••••.••.•..••••• PDSSPARAFPPSKSCVTKPEATATSTSPSNFYGNSMYFVNPASA. • • • • . • • . • • • • • • • • • • . • . . • . . . . • • • • • • •• 395 
a5 ••...•......•..•...• SHVDRY •.•••••..••••••• FTQKEETESGSG. . . . • • • • • • . • . • • . • . . . • • • • • • • • . . • . . . • . . . • • . .• 385 
~3 ••.•....••..••••..•• DHVDRYSSPEKEESQPWKGKVLEKKKQKQLSDG. • • • • • • . . . . . . . . • • • • • • • • • . . • • . . • . . . • . • • • • • .• 384 
a3 •.......•...•..•... TSNEGNAQKPRPLYGAELSNLNCFSRAESKGCKEGYPCQDGM ..••••••••••..••••.••• CGYCHHRRIKISNF 413 
a4 HKMASAPRFWPEPEGEPPATSGTQSLHPPSPSFCVPL. DVPAEPGPSCKSPSDQLPPQQPLEAEKASPHPSPGPCRPPHGTQAPGLAKARSLSVQHM 471 
a7 •••••••••••••••••• EDKVRPACQHKQRRCSLASVEMSAVGPPPASNGNLLYIGFRGLDGVHCVPTPDSGW •••••••••••.•••••••••. 406 
~2 •.••••.•••••.•••.•••••.•......•••••••••..•..•••.••••••.........• AGAFGAEPAPVAGPG .••• RSGEPCGCGLREAV 428 
~4 ..••••••••••••••••••••••••.••••••••••••..••••..••••............• ASKSPAGSTPVAIPRDFWLRSSGRFRQDVQEAL 428 
a5 •.•.•...•....••.••...•...........•••......•..........•..................•......••.... PKSSRNTLEAAL 397 
~3 ...•.•••••.••..•••.•••.••...•••••••••...•.••••••••.••...•.•••••••••••..•..•••.•.•••.• EKVLVAFLEKAA 396 
a3 .•••....•................•..••..•.••.....•... SANLT •••.••..•.••• RSSSSESVDAV~SLS •••.••... ALSPEIKEAI 443 
a4 SSPGEAVEGGVRCRSRSIQYCVPRDDAAPEADGQAAGALASRNTHSAELPPPDQPSPCKCTCKKEPSSVSPSATVKTRSTKAPPPHLPLSPALTRAV 568 
a7 .•••••••..•••••••..••...•.••••.•••..•.•.••••.••••.....••••••••••.. CGRMACSPTHDEHLLHGGQPPEGDPDLAKIL 437 
-1MDIV---+ 
~2 DGVRFIADHMRSEDDDQSVSEDWKYVAMVIDRLFLWIFVFVCVFGTIGMFLQPLFQNYTTTTFLHSDHSAPSSK' 502 
~4 EGVSFIAQHMKNDDEDQSWEDWKYVAMVVDRLFLWVFMFVCVLGTVGLFLPPLFQTHAASEGPYAAQRD·.... 498 
a5 DSIRYITRHIMKENDVREVVEDWKFIAQVLDRMFLWTFLFVSIVGSLGLFVPVIYKWANILIPVHIGNANK·... 46B 
~3 DSIRYISRHvxKEHFISQWQDWKFVAQVLDRIFLWLFLIVSVTGSVLIFTPALKMWLHSYH*............ 458 
a3 QSVKYIAENMKAQNEAKEIQDDWKYVAMVIDRIFLWVFTLVCILGTAGLFLQPLMAREDA·.............. 503 
a4 EGVQYIADHLKAEDTDFSVKEDWKYVAMVIDRIFLWMFIIVCLLGTVGLFLPPWLAGMI*............... 627 
a7 EEVRYIANRFRCQDESEAVCSEWKFAACWDRLCLMAFSVFTIICTIGILMSAPNFVEA VSKDFA' • • • • • • . . • 502 
Fig. 2. Amino acid sequence alignment of the human nAChR a3,4,5,7- and ~2,3,4-subunits. Indicated are the positions of the predicted signal 
peptide, the conserved cysteine residues, the four putative transmembrane domains (TMD I-IV) and the cytoplasmic region. Underlined are the 
amino acids which differ from the published versions [8-14). Alignment and predicted motifs were obtained with the GCG program (Genetics 
Computer Group, Madison, WI, USA). 
the subunit coding region exactly from the start to the stop 
codon. A minimum number of PCR cycles was used to obtain 
enough material for cloning the PCR fragment in pUC18 for 
subsequent detennination of its nucleotide sequence. The 
cDNA prepared from the neuroblastoma cell lines SH-SY5Y 
and IMR-32 was the starting material for the PCR reactions. 
For the ~2-subunit we also used cDNA prepared from human 
frontal cortex tissue and for the ~3-subunit we also used adap-
ter-ligated oligo(dT)-primed cDNA prepared from human 
pons tissue. Using this nested PCR approach we were able 
to clone the human nAChR subunits a3,4,5 and ~2,3,4 from 
different sources (Table 2). 
The human nAChR subunit ~3 clones (isolated from hu-
man pons and the SH-SY5Y cell line) contained an open 
reading frame of 1374 nt, coding for a protein of 458 amino 
acids (Fig. 2). The human nAChR subunit ~4 clones (isolated 
from both neuroblastoma cell lines) contained an open read-
ing frame of 1494 bp, coding for a protein of 498 amino acids 
(Fig. 2). 
Compared to the published sequences [8-14], we found sev-
eral differences for the a3,4,5,7- and ~3,4-subunits (all nucleo-
tide sequences have been submitted to the Genbank database: 
accession numbers Y08415-Y08421). At the amino acid level 
this led to the following changes (Fig. 2; all residues are in-
dicated in one-letter code and numbered independently in the 
published as well as in our sequence counting the predicted 
initiator methionine as I in either case): for the a3-subunit 
[10], CRA (11-13)->LSPP (11-14), G (99)->D (100), TT 
(131,132)->DD (132,133), S (234)->1 (235), V (429)->L 
(430); for the a5-subunit [12], ALRSSRARRAAR -> RC-
GLAGAAGGAQ (23-34), S -> V (128), S -> C (365), T -> R 
(405); for the a7-subunit [13], G->A (II); for the ~3-subunit 
[8], EWK (1-3) -> LFQ (36-38); for the ~4-subunit [9], DE 
(25,26)->EQ (73,74). For the a4-subunit no changes were 
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Fig. 3. Northern blots of the SH-SY5Y cell line showing mouse 
l3-actin (2 h exposure) and the human neuronal nAChR subunits 
132, 134, a3 (16 h exposure) and a7 (88 h exposure). 
predicted at the amino acid level. All the differences were 
found in both the clones isolated from the SH-SY5Y and 
the IMR-32 cell line (for ~3 the SH-SY5Y cell line and human 
pons). 
3.3. Northern blot analysis 
Full-length clones of the human nAChR a3,4,5,7- and 
~2,3,4-subunits were used to probe Northern blots containing 
3 ~g polyA + mRNA isolated from the SH-SY5Y neuroblas-
toma cell line. As a positive control probe, a full-length mouse 
~-actin (92% identical to the homologous human sequence) 
cDNA was used. Blots were washed for 16 h at a final strin-
gency of 0.1 xSSC and 0.1% (w:v) SDS. After a 2 h exposure, 
a strong signal of a 1.8 kb ~-actin transcript (Fig. 3) was 
observed as expected [16]. After a 16 h exposure, expression 
of the 3.0 kb a3, the 2.4 kb ~4 and the 5.6 kb ~2 transcripts 
can be detected in the SH-SY5Y cell line. After an 88 h ex-
posure three a7 transcripts of 5.7 kb, 3.1 kb and 1.9 kb can be 
detected in the SH-SY5Y cell line (Fig. 3). No specific tran-
scripts could be detected for the a4-, a5- and ~3-subunits in 
the SH-SY5Y cell line. 
4. Discussion 
With the 5' RACE method we obtained further 5' se-
quences of the human neuronal nAChR ~3- and ~4-subunits. 
Two adapter-ligated cDNA preparations were used: oli-
go(dT)-primed and internally primed (with gene-specific prim-
ers). Specific ~3-subunit 5' sequences were obtained only 
when starting from cDNA prepared with the ~3 gene-specific 
primer. Therefore it seems that preparing cDNA with gene-
specific primers enhances the chance of obtaining 5' end se-
quences by RACE. 
Willoughby et al. [8] showed on a Northern blot a 1.7 kb ~3 
transcript in human pons. Their sequence showed a duplica-
tion of 60 nt at the 3' end which we were not able to detect. 
Discounting this duplication, their partial sequence combined 
with our 5' RACE data yield a total of 1595 nt. Based on the 
Northern blot (Fig. 3), the presumably incomplete 3' end, and 
the typical length of a polyA tail, it is likely that the 5' end of 
our ~3 5' RACE clone is close to the 5' cap site of the ~3 
mRNA. 
For the ~4-subunit sequence we obtained in total 1588 nt. 
Based on the Northern blot (Fig. 3) there is still '" 800 nt 
unaccounted for, at least part of which corresponds to 3' 
UTR since the published sequence extends only to the stop 
codon. Because the two clones isolated have different 5' end 
sequences it is not likely that we reached the 5' cap site of the 
~4 mRNA. 
The neuroblastoma cell lines SH-SY5Y and IMR-32 proved 
to be an excellent source for isolation of human neuronal 
nAChR subunit cDNAs. From the SH-SY5Y cell line we 
isolated the a3,5,7- and ~2,3,4- subunit cDNAs. From the 
IMR-32 cell line we isolated the a3,4,5,7- and ~2,4-subunit 
cDNAs. Furthermore, we isolated the ~3-subunit cDNA from 
human pons tissue and the ~2-subunit cDNA from human 
frontal cortex. 
These neuronal nAChR subunit cDNAs were isolated with 
two different PCR approaches: TD-PCR and nested TD-
PCR. In the first approach the primers were designed to am-
plify the coding region exactly from start to stop codon and 
adding immediately upstream of the start codon a Kozak 
consensus sequence to improve translation in subsequent het-
erologous expression studies. This leads to cDNAs without 
any 5' or 3' UTRs, which are known to have occasionally a 
negative effect on heterologous expression [17]. With this ap-
proach only one subunit (a7) could be amplified. The problem 
with this approach is that the sequence of the primers is fixed 
and to obtain desired T m values only the length of the primers 
can be changed. In the case of the nAChR subunits this led to 
short GC-rich sense and long AT -rich anti-sense primers. 
Therefore, in the nested TD-PCR approach, PCR primers 
with properties as close as possible to the ideal (for criteria 
used, see Section 3) were designed upstream of the start and 
downstream of the stop codon. With these primers the other 
six nAChR subunits were amplified. To remove the 5' and 3' 
UTR sequences, the PCR products were used in a second 
nested PCR with the same primers as in the first PCR ap-
proach. Because in this reaction only a single template is 
available, and in large amounts, the amplification of the exact 
coding sequence of the nAChR subunits was possible. 
Whenever subunit clones from two different sources were 
obtained, their sequence was identical. Compared to pub-
lished sequences [8-14], only the ~2-subunit DNA sequence 
gave an 100% match [14]. Furthermore, the predicted a4-sub-
unit amino acid sequence is identical to the published version 
[12]. For all other subunit sequences, differences were found 
with published DNA and deduced amino acid sequences. 
These differences could be due to allelic variation, cDNA 
synthesis artefacts or PCR artefacts, or sequencing errors. 
Because our clones were isolated from two different sources, 
the first and second explanation seem unlikely. PCR condi-
tions to minimise error rates (e.g. DNA polymerases with 
proof-reading ability such as Pfu) were used. Also at least 
two independent (from different tissue or cell source) PCR 
clones were isolated for each subunit (except a4, where both 
clones were obtained from the IMR-32 cell line). Therefore, 
PCR artefacts are also an unlikely explanation. Furthermore, 
all clones were fully sequenced on both strands, virtually ex-
cluding sequencing errors. 
The human neuronal nAChR ~3- and ~4-subunits show 
94% and 89% amino acid sequence identity compared to the 
314 
rat neuronal nAChR ~3- [18] and ~4- [19] subunits, respec-
tively. Stop codons were found upstream of the AUG codon 
that opens the longest open reading frame, as well as a purine 
3 nt upstream of this predicted start codon (found in 97% of 
vertebrate mRNAs [20]). The length of the corresponding pre-
dicted rat and human amino acid sequences is approximately 
the same. Therefore, we conclude that we have cloned the full-
length coding region of the human neuronal nAChR ~3- and 
~4-subunits. 
In the SH-SYSY cell line the 3.0 kb a3 transcript appears 
most abundant, followed by the 2.4 kb ~4 transcript and the 
S.6 kb ~2 transcript. For the a7-subunit, at high stringency, 
we observe moderate expression of three transcripts (S.7 kb, 
3.1 kb and 1.9 kb), Peng et al. [13] also reported in the SH-
SYSY cell line three a7 transcripts of approximately the same 
size: S.9, 2.6, and 1.3 kb. The three transcripts could result 
from alternative splicing, or the use of different transcription 
start sites or polyadenylation sites. No mRNA transcripts 
could be detected on Northern blots for the a4-, as- and 
~3-subunits although the more sensitive PCR method shows 
that at least the as- and ~3-subunits are also expressed in the 
SH-SYSY cell line. This means that the SH-SYSY cell line 
expresses at least six neuronal nAChR subunits. Based on 
the PCR results the IMR-32 cell line expresses also at least 
six subunits: a3,4,S,7 and ~2,4. 
The question remains whether all these subunits form part 
of functional receptors. Expression of an a7 nAChR has been 
demonstrated in the SH-SYSY cell line, but this expression is 
not particularly high [13]. According to Wang et al. [21], most 
of the functional receptors in the SH-SYSY cell line consist of 
an a3/~2 or an a3/~4 combination. These data correspond 
well with the expression pattern of the nAChR subunits on 
our Northern blot. Wang et al. [21] also showed that as can 
form a functional receptor with the a3/~2 or the a3/~4 com-
bination expressed in oocytes and in the SH-SYSY cell line. 
To demonstrate this, they made use of mouse monoclonal 
antibody 210 which recognises the main immunogenic region 
amino acids NQIVTTNVRL [21] of the a5-subunit (amino 
acids 90-99, Fig. 2). Exactly the same sequence can be found 
in the ~3-subunit (amino acids 72-81, Fig. 2). Combining this 
information with our PCR data showing that the ~3-subunit 
is expressed in the SH-SY5Y cell line, it cannot be excluded 
that the ~3-subunit forms part of the nAChRs found in the 
SH-SY5Y cell line. Whether the ~3-subunit can indeed be part 
of a functional nAChR in the SH-SYSY cell line still remains 
to be proven. 
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